如何理解药物多晶型专利实质审查中的推定新颖性和单一性  

How to Understand the Novelty Presumption and Uniformity in the Patent Examination of Polymorphs

作　　者：张旋[1] Zhang Xuan(Patent Examination Cooperation Jiangsu Center of the Patent Office,CNIPA,Suzhou 215163,China)

机构地区：[1]国家知识产权局专利局专利审查协作江苏中心,江苏苏州215163

出　　处：《广东化工》2020年第8期76-77,共2页Guangdong Chemical Industry

摘　　要：药物多晶型的专利申请一直是药物专利布局重要的一环,而多晶型专利的权利要求需要借助物理或化学参数特征进行限定,而且由于多晶型以化合物为共同特征,化合物多为已知,不能构成特定技术特征,因此,多晶型专利的审查过程中经常涉及推定新颖性和单一性。本文对多晶型专利审查过程中,推定新颖性和单一性在不同情形下的适用进行了分析并提出个人的理解。Polymorph is an important part of the pharmaceutical patent arrangement;its claims are usually represented by physical or chemical parameters.The compound which is the common characteristics of polymorphs can’t be the specific characters as it’s usually known.Therefore,novelty presumption and uniformity are often discussed in the patent examination of polymorphs.Here,how to understand the novelty presumption and uniformity in different situations is expatiated.

关 键 词：多晶型 推定新颖性 单一性 

分 类 号：TQ[化学工程]